CN109666008A - 一种盐酸洛美利嗪的合成方法 - Google Patents
一种盐酸洛美利嗪的合成方法 Download PDFInfo
- Publication number
- CN109666008A CN109666008A CN201811650286.2A CN201811650286A CN109666008A CN 109666008 A CN109666008 A CN 109666008A CN 201811650286 A CN201811650286 A CN 201811650286A CN 109666008 A CN109666008 A CN 109666008A
- Authority
- CN
- China
- Prior art keywords
- piperazine
- trimethoxy
- methyl
- benzyl
- synthetic method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 229950007692 lomerizine Drugs 0.000 title claims abstract description 32
- 238000010189 synthetic method Methods 0.000 title claims abstract description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 32
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims abstract description 24
- -1 2,3,4- trimethoxy-benzene benzyl chlorides Chemical class 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 18
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019441 ethanol Nutrition 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- FHPNLCLHMNPLEW-UHFFFAOYSA-N 1-[chloro-(4-fluorophenyl)methyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(Cl)C1=CC=C(F)C=C1 FHPNLCLHMNPLEW-UHFFFAOYSA-N 0.000 claims abstract description 6
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000012065 filter cake Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 17
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 12
- 239000012043 crude product Substances 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- NSVMMMROPMMCOH-LLBVTOMBSA-N (2z,9e,11e)-octadeca-2,9,11-trien-5,7-diyn-1-ol Chemical compound CCCCCC\C=C\C=C\C#CC#CC\C=C/CO NSVMMMROPMMCOH-LLBVTOMBSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- MNRSGFGJPZSJIX-UHFFFAOYSA-N trans-bupleurynol Natural products CCCCCCC=CC=CC#CC#CC=CCO MNRSGFGJPZSJIX-UHFFFAOYSA-N 0.000 description 3
- UCTUXUGXIFRVGX-UHFFFAOYSA-N 2,3,4-trimethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(OC)=C1OC UCTUXUGXIFRVGX-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 2
- 229960000326 flunarizine Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010059109 Cerebral vasoconstriction Diseases 0.000 description 1
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 description 1
- PFJMCTBSOSRXCT-UHFFFAOYSA-N benzene;chloromethylbenzene Chemical compound C1=CC=CC=C1.ClCC1=CC=CC=C1 PFJMCTBSOSRXCT-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- QILSFLSDHQAZET-UHFFFAOYSA-N diphenylmethanol Chemical class C=1C=CC=CC=1C(O)C1=CC=CC=C1 QILSFLSDHQAZET-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002807 flunarizine hydrochloride Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Abstract
本发明属于药物制备技术领域,涉及一种盐酸洛美利嗪的合成方法。所述合成方法具体步骤为:1)2,3,4‑三甲氧基苯氯苄和1‑Boc‑哌嗪在碱性条件下,加热至40℃反应4h,然后加入盐酸得到1‑(2,3,4‑三甲氧基苄基)哌嗪;2)1‑(2,3,4‑三甲氧基苄基)哌嗪和4,4'‑二氟二苯甲基氯在三乙胺的条件下得到1‑(二(4‑氟苯基)甲基)‑4‑(2,3,4‑三甲氧基苄基)哌嗪;3)1‑(二(4‑氟苯基)甲基)‑4‑(2,3,4‑三甲氧基苄基)哌嗪在盐酸的条件下用乙醇和甲基叔丁基醚重结晶得到盐酸洛美利嗪。与现有技术相比,本发明所述的盐酸洛美利嗪的合成方法原料便宜,来源广泛,条件温和,且收率较高,化学纯度较高,处理简单,不需要精制。
Description
技术领域
本发明属于药物制备技术领域,具体来说,涉及到一种盐酸洛美利嗪的合成方法。
背景技术
盐酸洛美利嗪分子式为C27H32F2N2O3Cl2,白色或类白色结晶性粉末;无臭,具引湿性。本品在二甲基甲酰胺中易溶,在乙醇中溶解,在乙腈中略溶,在水或0.1mol/L盐酸溶液中极微解溶。盐酸洛美利嗪于1999年首先在日本上市,与盐酸氟桂利嗪(flunarizinedihydrochloride,西比灵)相比,具有高选择性扩张脑血管,并减小锥体外系副作用的特点。盐酸洛美利嗪是一种钙拮抗型偏头痛治疗药,属于第三代取代哌嗪类脑血管扩张药。主要通过钙通道阻滞而发挥作用,本品能显著扩张脑血管,从而缓解由脑血管收缩而引起的偏头痛。
盐酸洛美利嗪,其结构如下:
文献Synthesis,(12),1989-1991:2010采用2,3,4-三甲氧基溴苄与1-[双-(4-氟苯基)甲基]哌嗪进行反应,再经过硅胶柱分离。由于要用到硅胶柱分离除杂,不适合工业化生产。文献中国药物化学杂志,第13卷,第5期,297~298:以4-双苯基甲醇为起始原料,最后与2,3,4-三甲氧基苯甲醛经过Leuckart-Wallach反应得到。该路线较长,且收率比较低。文献中国医药工业杂志,2015,46(2),117~119:双(4-氟苯基)甲基酮经还原、氯代、取代等反应得到盐酸洛美利嗪,该路线后处理繁琐,且会产生大量酸性的废水废气,污染环境。此外,其中一步反应需要较高的温度,条件不温和。文献Radioisotopes,37(5),265-8,1988:将2,3,4-三甲氧基苯甲醛和4,4-二氟苯甲基哌嗪加热到150℃熔融,再滴加甲酸反应,成盐收率在50%左右,该工艺需加热温度较高,反应条件不温和,且收率较低。
发明内容
为解决上述技术问题,本发明提供了一种原料易得,反应条件温和,成本比较低,化学纯度较高、收率较高的盐酸洛美利嗪的合成方法。
本发明所述的一种盐酸洛美利嗪的合成方法,所述合成方法具体步骤为:
1)2,3,4-三甲氧基苯氯苄和1-Boc-哌嗪在碱性条件下,加热至40℃反应4h,然后加入盐酸得到1-(2,3,4-三甲氧基苄基)哌嗪;
2)1-(2,3,4-三甲氧基苄基)哌嗪和4,4'-二氟二苯甲基氯在三乙胺的条件下得到1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪;
3)1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪在盐酸的条件下用乙醇和甲基叔丁基醚重结晶得到盐酸洛美利嗪。
本发明所述的一种盐酸洛美利嗪的合成方法,所述步骤1)为:将2,3,4-三甲氧基苯氯苄0.1mol用200mL甲醇溶解,然后加入1-Boc-哌嗪0.12mol和2mol/L的氢氧化钠溶液25ml,在35℃~45℃条件下搅拌4h,然后滴加加入1mol/L的盐酸溶液100ml,控温35℃~45℃搅拌2h,然后减压浓缩掉甲醇,再加入100ml纯化水,用1mol/L的氢氧化钠溶液调pH至7~8,析出固体,将固体抽滤,滤饼用纯化水50ml淋洗2次,然后将滤饼于50℃的鼓风干燥箱中干燥8~10h,得到目标产物1-(2,3,4-三甲氧基苄基)哌嗪。
本发明所述的一种盐酸洛美利嗪的合成方法,所述步骤2)为:将1-(2,3,4-三甲氧基苄基)哌嗪0.09mol用200mL甲醇溶解,然后加入4,4'-二氟二苯甲基氯0.09mol和三乙胺0.18mol,在65℃~75℃条件下搅拌10h,然后降温至40℃~50℃,控温40~50℃减压浓缩至无馏分,得到1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品。
本发明所述的一种盐酸洛美利嗪的合成方法,所述步骤3)为:将1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品0.09mol用300mL乙醇溶解,然后加入盐酸40g,在40℃~50℃条件下搅拌2h,然后控温40℃~50℃减压浓缩至无馏分,再加入100ml甲基叔丁基醚,控温0~15℃搅拌析晶4小时,然后抽滤,滤饼用l0~15℃的甲基叔丁基醚10ml淋洗一次,然后将滤饼置于真空干燥箱中,在35~45℃、真空度≥0.06MPa的条件下干燥8~10h,得到目标产物盐酸洛美利嗪。
与现有技术相比,本发明所述的盐酸洛美利嗪的合成方法原料便宜,来源广泛,条件温和,且收率较高,化学纯度较高,处理简单,不需要精制。
具体实施方式
下面结合具体实施例对本发明所述的盐酸洛美利嗪的合成方法做进一步说明,但是本发明的保护范围并不限于此。
实施例1
盐酸洛美利嗪的合成路线
1-(2,3,4-三甲氧基苄基)哌嗪的制备
将2,3,4-三甲氧基苯氯苄(21.7g,0.1mol)用200mL甲醇溶解,然后加入1-Boc-哌嗪(22.4g,0.12mol)和2mol/L的氢氧化钠溶液25ml,在35℃~45℃条件下搅拌4h,然后滴加加入1mol/L的盐酸溶液100ml,控温35℃~45℃搅拌2h,然后减压浓缩掉甲醇,再加入100ml纯化水,用1mol/L的氢氧化钠溶液调pH至7~8,析出固体,将固体抽滤,滤饼用纯化水50ml淋洗2次,然后将滤饼于50℃的鼓风干燥箱中干燥8~10h,得到目标产物1-(2,3,4-三甲氧基苄基)哌嗪24.5g,收率为92.1%。
1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪的制备
将1-(2,3,4-三甲氧基苄基)哌嗪(24.0g,0.09mol)用200mL甲醇溶解,然后加入4,4'-二氟二苯甲基氯(21.5g,0.09mol)和三乙胺(18.2g,0.18mol),在65℃~75℃条件下搅拌10h,然后降温至40℃~50℃,控温40~50℃减压浓缩至无馏分,得到1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品。
盐酸洛美利嗪的制备
将1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品(理论量为42.2g,0.09mol)用300mL乙醇溶解,然后加入盐酸40g,在45℃条件下搅拌2h,然后控温45℃减压浓缩至无馏分,再加入100ml甲基叔丁基醚,控温10℃搅拌析晶4小时,然后抽滤,滤饼用l3℃的甲基叔丁基醚10ml淋洗一次,然后将滤饼置于真空干燥箱中,在40℃、真空度-(≥0.06MPa)的条件下干燥9h,得到目标产物盐酸洛美利嗪34.9g,两步收率为71.6%。
实施例2
前述步骤与实施例1相同,成盐时将1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品(理论量为42.2g,0.09mol)用300mL乙醇溶解,然后加入盐酸40g,在45℃条件下搅拌2h,然后控温45℃减压浓缩至无馏分,再加入100ml甲基叔丁基醚以及柴胡炔醇C2.5g,控温10℃搅拌析晶4小时,然后抽滤,滤饼用l3℃的甲基叔丁基醚10ml淋洗一次,然后将滤饼置于真空干燥箱中,在40℃、真空度-(≥0.06MPa)的条件下干燥9h,得到目标产物盐酸洛美利嗪36.7g,两步收率为75.3%。
实施例3
前述步骤与实施例1相同,成盐时将1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品(理论量为42.2g,0.09mol)用300mL乙醇溶解,然后加入盐酸40g,在45℃条件下搅拌2h,然后控温45℃减压浓缩至无馏分,再加入100ml甲基叔丁基醚以及柴胡炔醇A2.5g,控温10℃搅拌析晶4小时,然后抽滤,滤饼用l3℃的甲基叔丁基醚10ml淋洗一次,然后将滤饼置于真空干燥箱中,在40℃、真空度-(≥0.06MPa)的条件下干燥9h,得到目标产物盐酸洛美利嗪42.6g,两步收率为87.4%。
实施例4
前述步骤与实施例1相同,成盐时将1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品(理论量为42.2g,0.09mol)用300mL乙醇溶解,然后加入盐酸40g,在45℃条件下搅拌2h,然后控温45℃减压浓缩至无馏分,再加入100ml甲基叔丁基醚以及柴胡炔醇2.5g,控温10℃搅拌析晶4小时,然后抽滤,滤饼用l3℃的甲基叔丁基醚10ml淋洗一次,然后将滤饼置于真空干燥箱中,在40℃、真空度-(≥0.06MPa)的条件下干燥9h,得到目标产物盐酸洛美利嗪31.3g,两步收率为64.2%。
Claims (4)
1.一种盐酸洛美利嗪的合成方法,其特征在于,所述合成方法具体步骤为:
1)2,3,4-三甲氧基苯氯苄和1-Boc-哌嗪在碱性条件下,加热至40℃反应4h,然后加入盐酸得到1-(2,3,4-三甲氧基苄基)哌嗪;
2)1-(2,3,4-三甲氧基苄基)哌嗪和4,4'-二氟二苯甲基氯在三乙胺的条件下得到1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪;
3)1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪在盐酸的条件下用乙醇和甲基叔丁基醚重结晶得到盐酸洛美利嗪。
2.根据权利要求1所述盐酸洛美利嗪的合成方法,其特征在于,所述步骤1)为:将2,3,4-三甲氧基苯氯苄0.1mol用200mL甲醇溶解,然后加入1-Boc-哌嗪0.12mol和2mol/L的氢氧化钠溶液25ml,在35℃~45℃条件下搅拌4h,然后滴加加入1mol/L的盐酸溶液100ml,控温35℃~45℃搅拌2h,然后减压浓缩掉甲醇,再加入100ml纯化水,用1mol/L的氢氧化钠溶液调pH至7~8,析出固体,将固体抽滤,滤饼用纯化水50ml淋洗2次,然后将滤饼于50℃的鼓风干燥箱中干燥8~10h,得到目标产物1-(2,3,4-三甲氧基苄基)哌嗪。
3.根据权利要求1所述盐酸洛美利嗪的合成方法,其特征在于,所述步骤2)为:将1-(2,3,4-三甲氧基苄基)哌嗪0.09mol用200mL甲醇溶解,然后加入4,4'-二氟二苯甲基氯0.09mol和三乙胺0.18mol,在65℃~75℃条件下搅拌10h,然后降温至40℃~50℃,控温40~50℃减压浓缩至无馏分,得到1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品。
4.根据权利要求1所述盐酸洛美利嗪的合成方法,其特征在于,所述步骤3)为:将1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧基苄基)哌嗪粗品0.09mol用300mL乙醇溶解,然后加入盐酸40g,在40℃~50℃条件下搅拌2h,然后控温40℃~50℃减压浓缩至无馏分,再加入100ml甲基叔丁基醚,控温0~15℃搅拌析晶4小时,然后抽滤,滤饼用l0~15℃的甲基叔丁基醚10ml淋洗一次,然后将滤饼置于真空干燥箱中,在35~45℃、真空度≥0.06MPa的条件下干燥8~10h,得到目标产物盐酸洛美利嗪。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811650286.2A CN109666008A (zh) | 2018-12-31 | 2018-12-31 | 一种盐酸洛美利嗪的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811650286.2A CN109666008A (zh) | 2018-12-31 | 2018-12-31 | 一种盐酸洛美利嗪的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109666008A true CN109666008A (zh) | 2019-04-23 |
Family
ID=66147430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811650286.2A Pending CN109666008A (zh) | 2018-12-31 | 2018-12-31 | 一种盐酸洛美利嗪的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109666008A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0159566A1 (en) * | 1984-03-30 | 1985-10-30 | Kanebo, Ltd. | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient |
CN105175359A (zh) * | 2015-07-31 | 2015-12-23 | 四川省百草生物药业有限公司 | 一种盐酸洛美利嗪同分异构体及其制备方法 |
-
2018
- 2018-12-31 CN CN201811650286.2A patent/CN109666008A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0159566A1 (en) * | 1984-03-30 | 1985-10-30 | Kanebo, Ltd. | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient |
CN105175359A (zh) * | 2015-07-31 | 2015-12-23 | 四川省百草生物药业有限公司 | 一种盐酸洛美利嗪同分异构体及其制备方法 |
Non-Patent Citations (2)
Title |
---|
李爱军 等: "盐酸洛美利嗪的合成", 《中国医药工业杂志》 * |
王文浩 等: "曲美他嗪合成方法的改进", 《中国药物化学杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013026391A1 (zh) | 嘧菌酯及其合成中专用中间体的合成方法 | |
CN110627736B (zh) | 一种1-苯基-5-羟基四氮唑的回收利用方法 | |
CN112645869A (zh) | 一种马来酸氯苯那敏中间体的制备方法 | |
CN104447690A (zh) | 一锅法合成氯吡啶硝基亚甲基咪唑烷的方法 | |
CN104529872B (zh) | 一种盐酸贝尼地平中间体的合成方法 | |
CN109456329A (zh) | 一种泛昔洛韦的制备方法 | |
CN109666008A (zh) | 一种盐酸洛美利嗪的合成方法 | |
CN101891693B (zh) | 一种氟康唑的制备方法 | |
CN103588765A (zh) | 阿齐沙坦酯或其盐的合成方法及其中间体和中间体的合成方法 | |
CN104109135B (zh) | 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法 | |
CN109867695B (zh) | 一种匹伐他汀钙中间体的新制备方法 | |
CN115710221A (zh) | 一种孟鲁司特钠中间体的合成方法 | |
CN105693596A (zh) | 1-苄基-4-哌啶甲醛的制备方法 | |
CN108409557A (zh) | 布瓦西坦新中间体及其合成方法和应用 | |
CN113185508A (zh) | 一种制备高纯度高收率鲁拉西酮的方法 | |
CN107879992A (zh) | 一种(1‑甲基‑1h‑[1,2,4]三唑‑3‑基)‑甲醇的制备方法 | |
CN103896859B (zh) | 合成胞嘧啶的工艺 | |
CN107556260B (zh) | 一种乙螨唑制备方法 | |
CN107915694A (zh) | 1‑[2‑(2,4‑二甲基苯基巯基)苯基]哌嗪盐酸盐及其制备方法 | |
CN108727214B (zh) | 一种麻醉剂丁哌卡因杂质的合成方法 | |
CN101525310B (zh) | 1-苯甲酰基-3-(2-羟基-1,1-二甲基乙基)硫脲的合成方法 | |
CN103848812B (zh) | 精制伊马替尼的方法 | |
CN109651234A (zh) | 一种盐酸多奈哌齐的合成方法 | |
FI95468B (fi) | Parannettu menetelmä käyttökelpoisten piperidiinijohdannaisten valmistamiseksi | |
CN113582920B (zh) | 一种4-(4-吡啶基)吗啉的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190423 |